MedTech & Diagnostics

Tandem Diabetes Care Executive Compensation (FY25)

Name: Tandem Diabetes Care (TNDM) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

TNDM · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

John Sheridan

Latest say-on-pay support

May 20, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on Tandem Diabetes Care

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

Data as of October 22, 2026Latest filing (8-K): May 21, 2026

12 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Tandem Diabetes Care brief$1,500Get the executive brief

Velarion Member, one year

261 figures on this page: 253 cited to the filing that reported them, 8 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is Tandem Diabetes Care's chief executive and what were they paid?

Total compensation for John Sheridan, President and Chief Executive Officer, came to $6,858,503 in fiscal 2025. Sheridan's total moved 19.6% lower from the $8,526,238 reported for fiscal 2024.

What was Tandem Diabetes Care's say-on-pay result?

The say-on-pay proposal drew 97.2% of votes cast including abstentions in favor at the meeting held May 20, 2026 for fiscal 2025.

Which companies are in Tandem Diabetes Care's peer group?

The disclosed peer group names AngioDynamics, Artivion, AtriCure, CONMED and Dexcom, among others.

What is Tandem Diabetes Care's chief executive pay ratio?

For fiscal 2025, the company reported a chief executive pay ratio of 73:1, against median employee compensation of $94,564.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
John Sheridan President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Susan Morrison Executive Vice President, Chief Administrative Officer	◇	—	◇	◇	◇	—	◇	◇
David Berger Executive Vice President, Chief Operating Officer	◇	—	◇	◇	◇	—	◇	◇
Leigh Vosseller Executive Vice President, Chief Financial Officer and Treasurer	◇	—	◇	◇	◇	—	◇	◇
Brian Hansen Executive Vice President, Chief Commercial Officer	◇	—	◇	◇	◇	—	◇	◇
Elizabeth Gasser Executive Vice President, Chief Strategy Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
John Sheridan President and Chief Executive Officer	◇	—	◇	—	◇	—	◇	◇
Mark Novara Executive Vice President, Chief Commercial Officer	◇	—	◇	—	◇	—	◇	◇
Leigh Vosseller Executive Vice President, Chief Financial Officer and Treasurer	◇	—	◇	—	◇	—	◇	◇
Elizabeth Gasser Executive Vice President, Chief Strategy and Product Officer	◇	—	◇	—	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
John Sheridan President and Chief Executive Officer	◇	—	◇	—	◇	—	◇	◇
Leigh Vosseller Executive Vice President, Chief Financial Officer and Treasurer	◇	—	◇	—	◇	—	◇	◇
Jean-Claude Kyrillos Executive Vice President and Chief Operating Officer	◇	—	◇	—	◇	—	◇	◇
Susan Morrison Executive Vice President and Chief Administrative Officer	◇	—	◇	—	◇	—	◇	◇
Elizabeth Gasser Executive Vice President and Chief Strategy and Product Officer	◇	—	◇	—	◇	—	◇	◇
Mark Novara Executive Vice President and Chief Commercial Officer	◇	—	◇	—	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
John Sheridan President and Chief Executive Officer	◇	—	◇	—	◇	—	◇	◇
Mark Novara Executive Vice President and Chief Commercial Officer	◇	—	◇	—	◇	—	◇	◇
Leigh Vosseller Executive Vice President, Chief Financial Officer and Treasurer	◇	—	◇	—	◇	—	◇	◇
Elizabeth Gasser Executive Vice President and Chief Strategy and Product Officer	◇	—	◇	—	◇	—	◇	◇
Shannon Hansen Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary	◇	—	◇	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Elizabeth Gasser	PSU	◇	◇	◇	◇	◇	—	◇
John Sheridan	PSU	◇	◇	◇	◇	◇	—	◇
Leigh Vosseller	PSU	◇	◇	◇	◇	◇	—	◇
Mark Novara	PSU	◇	◇	◇	◇	◇	—	◇
Shannon Hansen	PSU	◇	◇	◇	◇	◇	—	◇

Fiscal 2022, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Leigh Vosseller	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
John Sheridan	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Mark Novara	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Shannon Hansen	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
Elizabeth Gasser	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Sandra Beaver	◇	◇	—	—	—	—	◇
Rebecca Robertson	◇	◇	—	—	—	—	◇
Christopher Twomey	◇	◇	—	—	—	—	◇
Kathleen McGroddy-Goetz	◇	◇	—	—	—	—	◇
Rajwant Sodhi	◇	◇	—	—	—	—	◇
Peyton Howell	◇	◇	—	—	—	—	◇
Joao Malagueira	◇	◇	—	—	—	—	◇
Myoungil Cha	◇	◇	—	—	—	—	◇

John Sheridan served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Stock ownership guideline: Stock ownership guidelines for directors and members of executive management

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

AngioDynamics ANGO
Artivion AORT
AtriCure ATRC
CONMED CNMD
Dexcom DXCM
Glaukos GKOS
Globus Medical GMED
Haemonetics HAE
ICU Medical ICUI
Inogen INGN
Inspire Medical Systems INSP
Insulet PODD
iRhythm Technologies IRTC
LivaNova PLC LIVN
Masimo MASI
Nevro NVRO
QuidelOrtho QDEL
STAAR Surgical STAA

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	May 20, 2026	=	◇	◇	◇
2024	May 21, 2025	=	◇	◇	◇
2023	May 22, 2024	=	◇	◇	◇
2022	May 24, 2023	=	◇	◇	◇
2021	May 25, 2022	=	◇	◇	◇
2020	May 18, 2021	=	◇	◇	◇
2019	May 27, 2020	=	◇	◇	◇
2018	June 18, 2019	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- John Sheridan (President and Chief Executive Officer), FY2025 total compensation $6,858,503 (base salary $790,583) [exec_comp, SEC accession 0001438133-26-000034, filed 2026-04-07]

What this page does not include

Everything above is a fact Tandem Diabetes Care disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Tandem Diabetes Care sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

261 figures on this page: 253 cited to the filing that reported them, 8 calculated from figures it prints.

253 cited to the filing

8 calculated from the filing

Documents cited

8-K, filed May 21, 2026
0001438133-26-000070
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 7, 2026
0001438133-26-000034
DIRECTOR COMPENSATION PROGRAM FOR 2025 · DIRECTOR COMPENSATION TABLE · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END · SUMMARY COMPENSATION TABLE
8-K, filed May 23, 2025
0001438133-25-000112
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 8, 2025
0001438133-25-000058
SUMMARY COMPENSATION TABLE
8-K, filed May 23, 2024
0001438133-24-000118
DEF 14A, filed April 9, 2024
0001438133-24-000076
Summary Compensation Table
8-K, filed May 26, 2023
0001438133-23-000094
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 12, 2023
0001438133-23-000058
Executive Compensation Tables
8-K, filed May 27, 2022
0001438133-22-000106
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 19, 2021
0001438133-21-000036
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 28, 2020
0001438133-20-000069
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 19, 2019
0001564590-19-022812
Item 5.07 Submission of Matters to a Vote of Security Holders

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Tandem Diabetes Care executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/TNDM (accessed 2026).

Short form: data: Velarion

The paid brief for Tandem Diabetes Care

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

12 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/TNDM/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Tandem Diabetes Care executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Tandem Diabetes Care and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & Diagnostics CEO pay ratio — MedTech & Diagnostics Say-on-pay support — MedTech & Diagnostics

Peers Tandem Diabetes Care discloses

The companies named in TNDM's own disclosed peer group.

AngioDynamics Artivion AtriCure CONMED Dexcom Glaukos Globus Medical Haemonetics ICU Medical Inogen Inspire Medical Systems Insulet iRhythm Technologies LivaNova PLC Masimo Nevro QuidelOrtho STAAR Surgical

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Tandem Diabetes Care

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for Tandem Diabetes Care

MedTech & Diagnostics rankings

Peers Tandem Diabetes Care discloses

Terms on this page